Early recurrence risk stratification of hepatocellular carcinoma receiving preoperative radiotherapy: Incorporating clinical and imaging features across treatment phases

doi:10.3748/wjg.v32.i23.118308

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 23

This Article

(21)

(32)

(0)

(421)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jun 21, 2026; 32(23): 118308
Published online Jun 21, 2026. doi: 10.3748/wjg.v32.i23.118308

Table 2 Preoperative and postoperative characteristics of patients, n (%) or median (interquartile range)

Characteristics	Total (n = 81)	ER group (n = 37)	Non-ER group (n = 44)	P value
Preoperative clinical factors
TACE prior to RT	5 (6.2)	3 (8.1)	2 (4.5)	0.656
Concurrent systemic therapy	41 (50.6)	18 (48.6)	23 (52.3)	0.745
Targeted therapy	34 (82.9)	13 (72.2)	21 (91.3)
Targeted therapy plus immunotherapy	4 (9.8)	3 (16.7)	1 (4.3)
Immunotherapy	3 (7.3)	2 (11.1)	1 (4.3)
TACE after RT	8 (9.9)	5 (13.5)	3 (6.8)	0.459
Preoperative AFP > 400 ng/mL	9 (11.1)	8 (21.6)	1 (2.3)	0.010^a
Preoperative PLT count < 100 × 10⁹/L	20 (24.7)	11 (29.7)	9 (20.5)	0.335
Preoperative ALT > 40 U/L	17 (21.0)	6 (16.2)	11 (25.0)	0.334
Preoperative AST > 40 U/L	20 (24.7)	7 (18.9)	13 (29.5)	0.269
Preoperative GGT > 60 U/L	50 (61.7)	24 (64.9)	26 (59.1)	0.594
Preoperative TBIL > 21 μmol/L	6 (7.4)	1 (2.7)	5 (11.4)	0.212
Preoperative albumin < 40 g/L	28 (34.6)	14 (37.8)	14 (31.8)	0.570
Preoperative ALBI grade 2	26 (32.1)	11 (29.7)	15 (34.1)	0.675
Imaging features
Early response by RECIST				0.370
CR + PR	26 (32.1)	10 (27.0)	16 (36.4)
SD + PD	55 (67.9)	27 (73.0)	28 (63.6)
Early response by mRECIST				0.264
CR + PR	47 (58.0)	19 (51.4)	28 (63.6)
SD + PD	34 (42.0)	18 (48.6)	16 (36.4)
Preoperative response by RECIST				0.842
CR + PR	36 (44.4)	16 (43.2)	20 (45.5)
SD + PD	45 (55.6)	21 (56.8)	24 (54.5)
Preoperative response by mRECIST				0.213
CR + PR	56 (69.1)	23 (62.2)	33 (75.0)
SD + PD	25 (30.9)	14 (37.8)	11 (25.0)
Preoperative CR by mRECIST	18 (22.2)	4 (10.8)	14 (31.8)	0.023^a
Tumor ADC (× 10^-3 mm²/second)	1.47 (1.31-1.69)	1.47 (1.27-1.65)	1.48 (1.31-1.72)	0.513
Tumor-to-liver ADC ratio	1.20 (1.09-1.46)	1.20 (1.01-1.44)	1.21 (1.10-1.46)	0.431
ΔADC%	28.3 (13.4-42.2)	28.3 (12.4-40.7)	28.2 (17.2-46.5)	0.615
Pathological factors
Major pathological response	32 (39.5)	13 (35.1)	19 (43.2)	0.461
Pathological complete response	8 (9.9)	2 (5.4)	6 (13.6)	0.279
Poor tumor differentiation	39 (48.1)	18 (48.6)	21 (47.7)	0.934
MVI	22 (27.2)	14 (37.8)	8 (18.2)	0.048^a
Satellite nodules	8 (9.9)	6 (16.2)	2 (4.5)	0.133
Invasion of liver surface	25 (30.9)	13 (35.1)	12 (27.3)	0.445

^aP < 0.05.

ER: Early recurrence; RT: Radiotherapy; TACE: Transarterial chemoembolization; AFP: Alpha-fetoprotein; PLT: Platelet count; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transpeptidase; TBIL: Total bilirubin; ALBI: Albumin-bilirubin; RECIST: Response Evaluation Criteria in Solid Tumor; mRECIST: Modified Response Evaluation Criteria in Solid Tumor; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ADC: Apparent diffusion coefficient; MVI: Microvascular invasion.

Full Size Table

Citation: Cong R, Chen B, Cheng SN, Zhai YR, Wu F, Feng B, Wang LY, Chen ZW, Zhu YJ, Ma XH, Zhao XM. Early recurrence risk stratification of hepatocellular carcinoma receiving preoperative radiotherapy: Incorporating clinical and imaging features across treatment phases. World J Gastroenterol 2026; 32(23): 118308
URL: https://www.wjgnet.com/1007-9327/full/v32/i23/118308.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i23.118308

Cong R, Chen B, Cheng SN, Zhai YR, Wu F, Feng B, Wang LY, Chen ZW, Zhu YJ, Ma XH, Zhao XM. Early recurrence risk stratification of hepatocellular carcinoma receiving preoperative radiotherapy: Incorporating clinical and imaging features across treatment phases. World J Gastroenterol 2026; 32(23): 118308 [DOI: 10.3748/wjg.v32.i23.118308]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.